Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Ginkgo Bioworks Lifts Guidance After Mixed Q2 Results; Shares Surge

Published 08/15/2022, 04:13 PM
Updated 08/15/2022, 04:28 PM
© Reuters.

© Reuters.

By Yasin Ebrahim

Investing.com -- Ginkgo Bioworks lifted its full-year guidance after reporting mixed second-quarter results. Losses were wider than expected as rising costs offset better-than-expected revenue. 

Ginkgo Bioworks Holdings (NYSE:DNA) stock was up more than 17% in aftermarket hours following the report.

The biotech company reported a loss of 41 cents, compared with Wall Street estimates for a loss of 14 cents. Revenue of $144.6 million topped estimates of $77.6 million.

Total operation expenses swelled to $791.5 million from $103.6 million a year earlier, driven by a surge in research and development costs and general and administrative expenses. 

Looking ahead, the company lifted its forecast for revenue to a range of $425 million to $440 million from $375 million to $390 million, compared with estimates of $384.5 million. 

Ahead of its pending acquisitions of Zymergen and Bayer (OTC:BAYRY)'s West Sacramento agricultural biologicals R&D facility, the company said the deals were expected to "significantly improve our platform and drive future value."

The Zymergen transaction is expected to close by Q1 2023, while the Bayer deal is expected to close in Q4 2022, it added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.